The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Foundation Medicine; Lilly; Merck Serono
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.
 
Yoon-Koo Kang
Consulting or Advisory Role - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly/ImClone; Merck Serono; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - DAEHWA Pharmaceutical; LSK Biopharma
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Ono Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Yee Chao
No Relationships to Disclose
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Hyun Cheol Chung
No Relationships to Disclose
 
Jen-Shi Chen
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Daiichi Sankyo; Lilly; MedImmune; MSD Oncology; Ono Pharmaceutical; orient EuroPharma; TTY Biopharm
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst)
 
Won Ki Kang
No Relationships to Disclose
 
Takaki Yoshikawa
Honoraria - Abbott Nutrition; Ajinomoto; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; Medtronic; Nihonkayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; MSD Oncology; Novartis
Research Funding - Chugai Pharma; Novartis; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Sang Cheul Oh
No Relationships to Disclose
 
Takao Tamura
No Relationships to Disclose
 
Keun-Wook Lee
Research Funding - Array BioPharma (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst)
 
Satoshi Morita
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical
 
Li-Tzong Chen
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm
Research Funding - Celgene (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); SynCoreBio (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)